The efficacy of combination of 20% azelaic acid with 0.05% tretinoin cream in the treatment of melasma
DOI:
https://doi.org/10.66344/jpad.21.4.2011.487Keywords:
20% azelaic acid, 0.05% tretinoin, melasmaAbstract
Background Melasma is a common acquired macular hyperpigmentation which involves mostly the sun exposed areas of face and neck. Objective To assess the efficacy of the combination of 20% azelaic acid with 0.05% tretinoin cream in the treatment of melasma. Patients and methods 30 patients of melasma were treated with daily night application of 20% azelaic acid and 0.05% tretinoin. Patients were assessed at 4, 8 and 12 weeks of treatment using melasma area severity index. Side effects during therapy were also noted. Results Majority i.e. 43% cases were between 26 to 30 years, 73.3% of patients were females and 56.7% were housewives, 70% were married and 86.7% were in middle class. Family history of melasma was positive in 66.7% cases. 93.3% patients had no history of systemic drug and 73.3% had no history of use of cosmetics. 93.3% of patients had malar area involvement and 6.7% had centrofacial area involvement. After treatment, the average MASI score decreased by 38.66% indicating moderate reduction of the severity of melasma. Burning sensation, itching and erythema developed in 50%, 30% and 16%, respectively. Conclusion The combination of 20% azelaic acid and 0.05% tretinoin cream in the treatment of melasma has a moderate lightening effect with some remarkable side effects.ÂReferences
Bandyobadhyay D. Topical treatment of melasma. Indian J Dermatol 2009; 54: 303-9.
Vazquez M, Maldonado H, Benmaman C, Sanchez JL. Melasma in men. A clinical and histologic study. Int J Dermatol 1988; 27: 25-7.
Management of pigmentary disorders - A report from the Pigmentary Disorders Academy. J Am Acad Dermatol 2006; 54: 272-81.
Pasricha JS, Khaitan BK, Dash S. Pigmentary disorder in India. Dermatol Clin 2007; 25: 243-522.
Rigopoulos D, Gregoriou S, Katasambas A. Hyperpigmentation and melasma. J Cosmet Dermatol 2007; 6: 195-202.
Kauh YC, Zachian TF. Melasma. Adv Exp Med Biol. 1999; 455: 491-9.
Taylor SC, Torok H, Jones T et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis 2003; 72: 67-72.
Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutic approaches to melasma, Dermatol Clin 2007; 25: 337-42.
Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006); 54 (5 Suppl): S272-81.
Pérez-Bernal A, Muñoz-Pérez MA, Camacho F. Management of facial hyperpigmentation. Am J Clin Dermatol 2000; 1: 261-68.
Pathak MA, Fitzpatrick TB, Parish JA. Treatment of melasma with hydroquinone. J Invest Dermatol 1993; 76: 324-9.
Sanchez NP. Melasma: a clinical, light microscopic, ultrastructural and immunofluorescence study. J Am Acad Dermatol 1981; 4: 698-710.
Lim JTE, Tham SN. GA peels in the treatment of melasma among Asian women. Dermatol Surg 1997; 23: 177- 9.
Cotellessa C, Peris K, Onorati MT et al. The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol Surg 1999; 25: 450-4.
Garcia A, Fulton JE. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996; 22: 443-7.
Kimbrough-Green CK, Griffiths CE, Finkel LJ et.al. Topical retinoic acid for melasma in black patient. A vehicle controlled clinical trial. Arch Dermatol 1994; 130: 727-33.
Sarkar R, Bhalla M, Kaur C, Kanwar AG. The combination of glycolic acid peels with a topical regiment in the treatment of melasma in dark skinned patients: A comparative study. Dermatol Surg 2002; 28: 828-32.
Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Br J Dermatol 2007; 156 (suppl. 1): 21-8.
Downloads
Published
How to Cite
Issue
Section
License
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
